Natixis Advisors LLC Sells 50,409 Shares of Bruker Corporation (NASDAQ:BRKR)

Key Points

• Natixis Advisors LLC reduced its stake in Bruker Corporation by 14.0%, now holding about 310,222 shares worth approximately $12.9 million.
• Bruker recently announced a quarterly dividend of $0.05 per share, resulting in an annualized yield of 0.6% with a payout ratio of 38.46%.
• Bruker reported a net margin of 2.31% and a revenue of $797.40 million for the last quarter, which fell short of analyst expectations.

Natixis Advisors LLC cut its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 14.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 310,222 shares of the medical research company's stock after selling 50,409 shares during the quarter. Natixis Advisors LLC owned 0.20% of Bruker worth $12,948,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of BRKR. Pinnacle Bancorp Inc. bought a new stake in shares of Bruker in the first quarter valued at $29,000. Allworth Financial LP boosted its position in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after acquiring an additional 364 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock worth $46,000 after buying an additional 800 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of Bruker by 54.2% during the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock worth $46,000 after acquiring an additional 390 shares during the last quarter. Finally, UMB Bank n.a. grew its position in Bruker by 45.8% during the first quarter. UMB Bank n.a. now owns 1,325 shares of the medical research company's stock valued at $55,000 after acquiring an additional 416 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Down 4.4%

Shares of NASDAQ:BRKR traded down $1.41 during trading on Wednesday, hitting $30.66. The company's stock had a trading volume of 5,943,048 shares, compared to its average volume of 2,433,492. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.74 and a current ratio of 1.61. The business has a 50 day moving average price of $39.83 and a two-hundred day moving average price of $43.12. The company has a market capitalization of $4.65 billion, a PE ratio of 58.96, a P/E/G ratio of 2.34 and a beta of 1.16. Bruker Corporation has a fifty-two week low of $30.23 and a fifty-two week high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million during the quarter, compared to analysts' expectations of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company's revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the business posted $0.52 earnings per share. As a group, research analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Monday, June 16th were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.7%. The ex-dividend date was Monday, June 16th. Bruker's payout ratio is currently 38.46%.

Analysts Set New Price Targets

Several research analysts recently commented on BRKR shares. Barclays set a $43.00 target price on shares of Bruker and gave the stock an "overweight" rating in a research note on Monday. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the company a "buy" rating in a research note on Monday. UBS Group dropped their price target on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Citigroup lowered their target price on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday. Finally, Wells Fargo & Company dropped their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Tuesday. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $51.30.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the stock in a transaction on Friday, June 6th. The stock was purchased at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the purchase, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 27.30% of the stock is currently owned by corporate insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.